Actually, that is not entirely true. Granted, when the company receives the final FDA response, such has to be announced within four days I think it is. Might be three.
However, if there are physical inspections required and scheduled, or conferences with physicians, or physical verification of signatures to documents, etc., etc., required by the FDA in order to complete a process or allow for the approval and such must be rescheduled due to medical emergencies that have arisen with a key member of the process, this does not have to be conveyed publicly/disclosed.
Further, if a new FDA application is in the works and required signatures that could not be obtained due to a medical emergency that caused a delay in the required persons meeting for such signatures, this would not be conveyed/disclosed.
When such matters are at last addressed and finalized, this is considered material and is released to the public.
The above are by no means anomalies.
That said, the next PR is either going to be a reiteration of what we already know is presently happening (I would like to think not as the company is well aware of shareholder sentiment about what is being considered "fluff" PR's) and that is a great deal whether many want to embrace this or not. OR we are going to be informed that the company has initiated something new and/or has a FDA decision on HemaXellerate.
